SUMMARY

Severe degenetative myxomatous mitral valve disease (DMMVD) is a common condition in dogs. Therefore, a clinical study was conducted to determine the effectiveness of different treatment protocols based on enalapril maleate, furosemide, spironolactone, and their associations, to treat dogs with DMMVD belonging to functional class II congestive heart failure (CHF). For this purpose, 20 dogs were divided into two groups (n = 10), where the first received enalapril maleate (0.5 mg/kg) and furosemide (2 mg/kg) and the second enalapril maleate spironolactone (1 mg/kg) and furosemide, administered once a day for 56 days. The dogs were evaluated four different times regarding clinical signs, radiographic, electrocardiographic, echocardiographic and blood pressure. However, hematological and biochemical-serum, which included mainly serum concentrations of angiotensin converting enzyme (ACE) and aldosterone, were implemented at the beginning and end of the experiment. The results were characterized by animals with mitral murmur grade III to V/VI with reduced clinical signs after administration of therapeutic protocols. Laboratory tests revealed significant reduction (p<0.01) for values of ACE and aldosterone in both groups. The radiographic examination showed significant reductions (p<0.05) in VHS and variable wave Pms ECG in both groups. Moreover, the Doppler echocardiography showed significant decrease (p<0.05) variables LVD d/s IVS d/s, mean LA/Ao, FS % and the speed of mitral valve regurgitation. Therefore, the analysis of the results showed the effectiveness of treatment protocols used, especially when combined with spironolactone. KEY-WORDS: Endocardiosis. Mitral valve. Canines